Description
The HRA-19 cell line was established from a primary human rectal adenocarcinoma present in a 66-year old male. The adenocarcinoma was well differentiated and determined to be Dukes' stage B. A clonal derivative of HRA-19 cell line is available. HRA-19 has stem cell properties and undergoes a multilineage differentiation in serum free medium. A number of genetically modified derivatives of HRA-19 are also available.
Adherent Suspension
Adherent
Suggested Medium
DMEM (High glucose Sigma D6546) + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Quality Control
HRA-19 Cell Line was tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Shippment
HRA-19 Cell Line will be shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
HRA-19 Cell Line is for research use only
